⚠️ Mechanism
Green Tea is a weak inhibitor of CYP1A2, which decreases metabolism of CYP1A2 substrates, potentially increasing their plasma concentrations and risk of adverse effects.
📋 Effect
Increased plasma levels of rasagiline (maoi), potentially leading to toxicity or enhanced adverse effects.
💊 Management
Monitor for increased adverse effects of rasagiline. Dose reduction may be necessary. Consider alternative supplement or consult healthcare provider.
Plain Language Summary
This combination can be moderately dangerous because green tea may cause the levels of your MAOI medication to build up in your body. This happens because the tea can slow down how your body processes the drug, which may increase your risk of side effects.
Source
Flockhart CYP450 Table (drug-interactions.medicine.iu.edu)
Supporting Research
The effect of Green green tea consumption on body mass index, lipoprotein, liver enzymes, and liver cancer: An updated systemic review incorporating a meta-analysis
Green Tea Consumption and Risk of Breast Cancer and Recurrence-A Systematic Review and Meta-Analysis of Observational Studies
Green tea (Camellia sinensis) for the prevention of cancer
The Effect of Antioxidant Polyphenol Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis
Green tea consumption and risk of pancreatic cancer: a meta-analysis
Safety and Effectiveness of Oral Nutraceuticals for Treating Acne: A Systematic Review
Dietary Strategies for Weight Loss Maintenance
Green and black tea for the primary prevention of cardiovascular disease
Medical Disclaimer: This interaction record is for informational and educational purposes only and does not constitute medical advice. Drug-supplement interactions can be dangerous. Always consult your healthcare provider or pharmacist before combining any supplement with prescription medications. Do not stop or change any medication without professional guidance.